Compare Alphabet Inc Class A (GOOGL) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs Sanofi SA — how do they compare? Alphabet Inc Class A trades at $354.47 (market cap $4.52T), while Sanofi SA trades at $44.22 (market cap $103.94B). The key difference: Alphabet Inc Class A is far larger — about 43.5× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (5.54%). Which is the better fit depends on your goals.
| GOOGL | SNY | |
|---|---|---|
Market Cap | $4.52T | $103.94B |
Sector | Media | Health |
52-Week High | $402.62 | $52.34 |
52-Week Low | $182.97 | $41.33 |
Enterprise Value | $4.49T | $120.43B |
Dividend Yield | 0.24% | 5.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $356.14, down 0.94% on the day, with strong technical support at $355 and resistance at $375. The stock shows bullish momentum in moving averages while oscillators remain neutral. Recent earnings consistently beat expectations, with Q1 2026 EPS of $5.11 significantly exceeding the $2.64 forecast. Revenue growth accelerated to $402.84 billion in 2025, with net income margins expanding to 32.8%.
Alphabet presents a compelling investment case with 85% analyst buy ratings and a $431.78 consensus price target representing 21% upside. Strong AI integration, YouTube price increases, and cloud partnerships drive growth, though regulatory scrutiny and tech sector volatility remain key risks. The company's robust cash flow generation and strategic investments position it well for sustained outperformance.
Sanofi (SNY) trades at $44.11, up 2.15% today, with a bullish technical signal supported by moving averages. The company shows strong fundamentals with a P/E of 19.37, net income margin of 15.95%, and consistent earnings beats in recent quarters. Recent FDA approval for Sarclisa's subcutaneous formulation and EU clearance for Cenrifki highlight pipeline progress, while a dividend of $2.42 per share underscores shareholder returns.
Outlook remains positive driven by Dupixent growth and new drug approvals, though risks include EU antitrust probes and competitive pressures. Analysts are mixed with 44% buy ratings, suggesting cautious optimism. The stock presents value with solid cash flow and profitability, but investors should monitor regulatory developments and pipeline execution for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
